Example: Heart Attack

Search clinical trials for: Treprostinil

Total 109 results

NCT03835676

Recruiting

Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension

Conditions: Pulmonary Hypertension
NCT03012646

Withdrawn

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
NCT03992755

Active, not recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Conditions: Primary Pulmonary Hypertension
NCT02498444

Active, not recruiting

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Conditions: Single Ventricle
NCT03399604

Completed

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Conditions: Primary Pulmonary Hypertension
NCT04005469

Not yet recruiting

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

Conditions: Ischemia Reperfusion Injury; Delayed Graft Function
NCT03055221

Completed

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension
NCT02663895

Completed

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Conditions: Systemic Sclerosis; Calcinosis
NCT03884465

Recruiting

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Conditions: Pulmonary Arterial Hypertension
NCT01481974

Active, not recruiting

Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

Conditions: Ischemia Reperfusion Injury
NCT02633293

Active, not recruiting

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema
NCT03016468

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Conditions: Pulmonary Arterial Hypertension
NCT03043651

Terminated

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Conditions: Pulmonary Hypertension Associated With HFpEF
NCT03794583

Enrolling by invitation

Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
NCT02882126

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT01758744

Completed

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1

Conditions: Pulmonary Hypertension; COPD
NCT02178566

Terminated

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
NCT01615627

Withdrawn

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Conditions: Pulmonary Arterial Hypertension
NCT03497689

Recruiting

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT03814317

Recruiting

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Conditions: Sarcoidosis; Precapillary Pulmonary Hypertension; Interstitial Lung Disease
NCT02893995

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT01153386

Completed

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Conditions: Pulmonary Arterial Hypertension
NCT03045029

Recruiting

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Conditions: Pulmonary Arterial Hypertension
NCT02603068

Withdrawn

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Conditions: Pulmonary Hypertension; Pulmonary Fibrosis
NCT02630316

Completed

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema